Thermo Fisher Scientific Inc. (NYSE:TMO) faces investor focus on pharma/biotech spending, revenue from deals like Clario, progress on the microbiology divestiture, new products, AI and global expansion even as it scrambles to patch a high‑severity flaw in its DNA analysis software—adding digital signatures and coordinating with CISA.
Previous Week Recap
- Thermo Fisher Traders Watch Pharma Spending: Thermo Fisher (TMO) traders: watch pharma/biotech spending, revenue from recent deals like Clario, microbiology divestiture progress, new product and AI adoption, and global expansion.
- Thermo Fisher Security Patch Issued: Thermo Fisher (TMO) disclosed a high-severity flaw in its DNA analysis software used by crime labs, issued a security patch adding digital file signatures, and is working with CISA.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.